Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
RegulatoryapprovedUbeslo®Evlarco®Positive
AI Analysis
Summary
Menarini Group and NewAmsterdam Pharma received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimib combination), marking the first worldwide approval of a CETP inhibitor. The approvals are supported by Phase 3 trials demonstrating significant LDL-C reductions with favorable tolerability.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimib fixed combination) as first-in-class treatments
Importance:9/10
Sentiment:
0.95
European approvalFirst-in-classObicetrapibLDL cholesterolBROADWAYBROOKLYNTANDEM
Related Companies
Read the original article
Published by PR Newswire Biotech on September 21, 2026 7:04 PM